Abstract
Introduction
Although protein-based therapeutics were seen as a risky and diffi cult fi eld
of endeavor, the biopharmaceutical industry's persistent pursuit of such
agents created a multi-billion-dollar marketplace and a host of life-saving
treatments. Now, as fi rst-generation drugs face patent expiry, the industry
is pursuing technological and commercial opportunities that it hopes will
yield the next generation of protein-based drugs, improving patient care and
expanding market share.
Get the Answers You Need to Shape Your Strategy
Companies are developing technologies that will remodel recombinant protein
and MAb therapeutics into next-generation drugs. What opportunities are
being pursued for improving protein therapeutics? How will next-generation
drugs improve upon their predecessors? Targeting protein therapeutics to
reduce adverse side effects is an important goal and includes the creation of
new classes of fusion proteins. Which companies are developing leading-edge
technologies? What other advantages do targeted therapeutics hold?
Researchers have developed promising new techniques for conjugating MAbs to
various payloads, such as adding cytotoxic agents or radioisotopes to
protein-based drugs. What are the advantages of these new protein
conjugation techniques? Which companies lead the field? Demand for protein
therapeutics grows each year, but manufacturing therapeutic proteins remains
expensive and time-consuming. How are companies reducing cost and the time
needed to produce recombinant proteins? Which methods are most promising?
View Cart
